<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4653570</article-id><article-id pub-id-type="publisher-id">1758-5996-7-S1-A57</article-id><article-id pub-id-type="doi">10.1186/1758-5996-7-S1-A57</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Barbieri</surname><given-names>Douglas Eugenio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dbarbieri@lilly.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Duan</surname><given-names>Ran</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Gross</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Linetzky</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>De Lana</surname><given-names>Janaina Martins</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Rojas</surname><given-names>Arturo</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Sposetti</surname><given-names>Georgina</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Stempa</surname><given-names>Oded</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Rodriguez</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, Brazil</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2015</year></pub-date><volume>7</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">20th Brazilian Diabetes Society Congress</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the Brazilian Diabetes Society.</named-content></supplement><fpage>A57</fpage><lpage>A57</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Barbieri et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Barbieri et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.dmsjournal.com/content/7/S1/A57"/><conference><conf-date>11-18 November 2015</conf-date><conf-name>20th Brazilian Diabetes Society Congress</conf-name><conf-loc>Porto Alegre, Brazil</conf-loc></conference></article-meta></front><body><sec><title>Background/aim</title><p>This post-hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation (Argentina, Brazil, and Mexico) of participants with type 2 diabetes mellitus (T2D).</p></sec><sec><title>Materials and methods</title><p>This phase 4, randomized, open-label, parallel-arm trial included participants aged 18&#x02013;75 yrs. with T2D who were taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone and had glycosylated hemoglobin (HbA1c) between &#x02265;7.5% and &#x02264;10.5% and fasting plasma glucose &#x02264;6.7 mmol/L (121 mg/dL). Participants were randomized 1: 1 to receive twice-daily LM25 (before breakfast and dinner) or basal insulin glargine (at bedtime) and IGL (before the largest daily meal) in addition to their existing dose of metformin and/or pioglitazone for 24 weeks. The primary efficacy outcome was the change in HbA1c from baseline to Week 24.</p></sec><sec><title>Results</title><p>A total of 162 participants (80 LM25; 82 IGL) with a mean (standard deviation [SD]) age of 57.3 (9.0) yrs. and body mass index of 31.3 (5.2) kg/m2 were included. The mean (SD) change in HbA1c (%) from baseline was -1.5 (1.0) in the LM25 group and -1.0 (1.2) in the IGL group (Figure <xref ref-type="fig" rid="F1">1</xref>). At Week 24, 35.1% of participants in the LM25 group and 31.6% of participants in the IGL group achieved the target HbA1c &#x0003c;7.0%. Fasting blood glucose and glycemic variability at Week 24 were similar between the 2 groups, as was the mean (SD) total daily insulin dose (LM25=61.0 [27.6] IU; IGL=60.6 [24.3] IU). The mean (SD) rate of total hypoglycemia per 30 days was numerically similar between the two groups (LM25=1.6 [2.2]; IGL=1.8 [2.6] [overall study period]). Mean (SD) weight gain from baseline to Week 24 was 2.4 (2.9) kg in the LM25 group and 1.0 (3.1) kg in the IGL group. Treatment-emergent adverse events were similar between the 2 groups.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Observed HbA1c levels at Baseline, Week 12, and Week 24 in patients receiving insulin lispro low mixture (LM25; 75% insulin lispro protamine suspension and 25% insulin lispro solution 25%) twice daily or basal insulin glargine once daily and prandial insulin lispro once daily (IGL). Abbreviation: HbA1c=glycosylated hemoglobin.</p></caption><graphic xlink:href="1758-5996-7-S1-A57-1"/></fig></sec><sec><title>Conclusions</title><p>The results of this post-hoc analysis in a Latin American population are consistent with the results reported in the trial-level population and suggest that both LM25 and IGL are viable treatment options for insulin intensification in patients with T2D who do not achieve glycemic control on basal insulin glargine. ClinicalTrials.gov Number: NCT01175824.</p></sec></body></article>